Table 2.
COMMANDER HF trial: overall results comparing rivaroxaban 2.5 mg twice-daily and with placebo on a background of standard care
| Outcome | Rivaroxaban 2.5 mg twice-daily | Placebo twice-daily | HR (95% CI) |
|---|---|---|---|
| N = 2507 | N = 2515 | ||
| Death, myocardial infarction, or stroke | 626 (25%) | 658 (26.2%) | 0.94 (0.84–1.05) |
| Death | 546 (21.8%) | 556 (22.1%) | 0.98 (0.87–1.10) |
| Myocardial infarction | 98 (3.9%) | 118 (4.7%) | 0.83 (0.63–1.08) |
| Stroke | 51 (2.0%) | 76 (3.0%) | 0.66 (0.47–0.95) |
| Composite of thromboembolic events: myocardial infarction, ischaemic stroke, sudden/unwitnessed deaths, symptomatic PE, symptomatic DVT | 328 (13.1%) | 390 (15.5%) | 0.83 (0.72–0.96) |